drugset / Trial / NCT05858853
Phase II/III of Recombinant Human Serum Albumin
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, position-controlled, parallel group phase II/III clinical study of recombinant human serum albumin (rHSA) in cirrhotic ascites patients.
Timeline
- Start
- 2023-05-24
- Primary completion
- 2023-09-15
- Completion
- 2023-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED | Protein / enzyme biologic | 10 g | Intravenous |
| Subject | HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED | Protein / enzyme biologic | 20 g | Intravenous |
| Subject | Human serum albumin | Protein / enzyme biologic | 10 g | — |
| Subject | Human serum albumin | Protein / enzyme biologic | 20 g | — |